PURPOSE: This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC). MATERIALS AND METHODS: Twenty-nine patients with newly diagnosed LARC treated between January 2014 and February 2018 were enrolled. Patients received long-course neoadjuvant chemoradiation prior to surgery. Plasma ctDNA was collected at baseline, preoperatively, and postoperatively. Next-generation sequencing was used to identify mutations in the primary tumor, and mutation-specific droplet digital polymerase chain reaction was used to assess mutation fraction in ctDNA. RESULTS: The median age was 54 years. The overall margin-negative, node-negative resection rate was 73% and was significantly higher among patients with undetectable preoperative ctDNA (n = 17, 88%) versus patients with detectable preoperative ctDNA (n = 9, 44%; P = .028). Undetectable ctDNA was also associated with more favorable neoadjuvant rectal scores (univariate linear regression, P = .029). Recurrence-free survival (RFS) was calculated for the subset (n = 19) who both underwent surgery and had postoperative ctDNA available. At a median follow-up of 20 months, patients with detectable postoperative ctDNA experienced poorer RFS (hazard ratio, 11.56; P = .007). All patients (4 of 4) with detectable postoperative ctDNA recurred (positive predictive value = 100%), whereas only 2 of 15 patients with undetectable ctDNA recurred (negative predictive value = 87%). CONCLUSION: Among patients treated with neoadjuvant chemoradiation for LARC, patients with undetectable preoperative ctDNA were more likely to have a favorable surgical outcome as measured by the rate of margin-negative, node-negative resections and neoadjuvant rectal score. Furthermore, we have confirmed prior reports indicating that detectable postoperative ctDNA is associated with worse RFS. Future prospective study is needed to assess the potential for ctDNA to assist with personalizing treatment for LARC.
PURPOSE: This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC). MATERIALS AND METHODS: Twenty-nine patients with newly diagnosed LARC treated between January 2014 and February 2018 were enrolled. Patients received long-course neoadjuvant chemoradiation prior to surgery. Plasma ctDNA was collected at baseline, preoperatively, and postoperatively. Next-generation sequencing was used to identify mutations in the primary tumor, and mutation-specific droplet digital polymerase chain reaction was used to assess mutation fraction in ctDNA. RESULTS: The median age was 54 years. The overall margin-negative, node-negative resection rate was 73% and was significantly higher among patients with undetectable preoperative ctDNA (n = 17, 88%) versus patients with detectable preoperative ctDNA (n = 9, 44%; P = .028). Undetectable ctDNA was also associated with more favorable neoadjuvant rectal scores (univariate linear regression, P = .029). Recurrence-free survival (RFS) was calculated for the subset (n = 19) who both underwent surgery and had postoperative ctDNA available. At a median follow-up of 20 months, patients with detectable postoperative ctDNA experienced poorer RFS (hazard ratio, 11.56; P = .007). All patients (4 of 4) with detectable postoperative ctDNA recurred (positive predictive value = 100%), whereas only 2 of 15 patients with undetectable ctDNA recurred (negative predictive value = 87%). CONCLUSION: Among patients treated with neoadjuvant chemoradiation for LARC, patients with undetectable preoperative ctDNA were more likely to have a favorable surgical outcome as measured by the rate of margin-negative, node-negative resections and neoadjuvant rectal score. Furthermore, we have confirmed prior reports indicating that detectable postoperative ctDNA is associated with worse RFS. Future prospective study is needed to assess the potential for ctDNA to assist with personalizing treatment for LARC.
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-08 Impact factor: 11.908
Authors: Mehlika Hazar-Rethinam; Marianna Kleyman; G Celine Han; David Liu; Leanne G Ahronian; Heather A Shahzade; Lifeng Chen; Aparna R Parikh; Jill N Allen; Jeffrey W Clark; Eunice L Kwak; Jason E Faris; Janet E Murphy; Theodore S Hong; Emily E Van Seventer; Brandon Nadres; Catriona B Hong; Joseph M Gurski; Nicholas A Jessop; Dora Dias-Santagata; A John Iafrate; Eliezer M Van Allen; Ryan B Corcoran Journal: Cancer Discov Date: 2018-02-05 Impact factor: 39.397
Authors: Jeanne Tie; Joshua D Cohen; Bert Volgestein; Peter Gibbs; Yuxuan Wang; Lu Li; Michael Christie; Koen Simons; Hany Elsaleh; Suzanne Kosmider; Rachel Wong; Desmond Yip; Margaret Lee; Ben Tran; David Rangiah; Matthew Burge; David Goldstein; Madhu Singh; Iain Skinner; Ian Faragher; Matthew Croxford; Carolyn Bampton; Andrew Haydon; Ian T Jones; Christos S Karapetis; Timothy Price; Mary J Schaefer; Jeanne Ptak; Lisa Dobbyn; Natallie Silliman; Isaac Kinde; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth Kinzler Journal: Gut Date: 2018-02-02 Impact factor: 23.059
Authors: Arvind Dasari; Van K Morris; Carmen J Allegra; Chloe Atreya; Al B Benson; Patrick Boland; Ki Chung; Mehmet S Copur; Ryan B Corcoran; Dustin A Deming; Andrea Dwyer; Maximilian Diehn; Cathy Eng; Thomas J George; Marc J Gollub; Rachel A Goodwin; Stanley R Hamilton; Jaclyn F Hechtman; Howard Hochster; Theodore S Hong; Federico Innocenti; Atif Iqbal; Samuel A Jacobs; Hagen F Kennecke; James J Lee; Christopher H Lieu; Heinz-Josef Lenz; O Wolf Lindwasser; Clara Montagut; Bruno Odisio; Fang-Shu Ou; Laura Porter; Kanwal Raghav; Deborah Schrag; Aaron J Scott; Qian Shi; John H Strickler; Alan Venook; Rona Yaeger; Greg Yothers; Y Nancy You; Jason A Zell; Scott Kopetz Journal: Nat Rev Clin Oncol Date: 2020-07-06 Impact factor: 65.011
Authors: Gianluca Mauri; Pietro Paolo Vitiello; Alberto Sogari; Giovanni Crisafulli; Andrea Sartore-Bianchi; Silvia Marsoni; Salvatore Siena; Alberto Bardelli Journal: Br J Cancer Date: 2022-03-09 Impact factor: 9.075
Authors: Jun Gong; Andrew Hendifar; Alexandra Gangi; Karen Zaghiyan; Katelyn Atkins; Yosef Nasseri; Zuri Murrell; Jane C Figueiredo; Sarah Salvy; Robert Haile; Megan Hitchins Journal: Cancers (Basel) Date: 2021-09-10 Impact factor: 6.639